Illumina Announces Preliminary Results Of Annual Meeting


(MENAFN- PR Newswire) Illumina shareholders
re-elect eight of nine Illumina directors

SAN DIEGO, May 25, 2023 /PRNewswire/ -- Illumina (NASDAQ: ilmn ), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders
have voted to elect eight of nine Illumina director nominees – Francis deSouza, Robert Epstein, MD, Frances Arnold, PhD, Caroline Dorsa, Scott Gottlieb, MD, Gary Guthart, PhD, Philip Schiller, and Sue Siegel, as well as Andrew Teno, to the Board of Directors. The Board thanks John Thompson for his board tenure and extraordinary leadership.

Illumina issued the following statement:

"Illumina thanks shareholders
for their continued support of the company, which remains committed to its mission of improving human health
by unlocking the power of the genome. We appreciate the constructive shareholder feedback throughout this process and are committed to delivering on our plan to accelerate shareholder value creation. We will continue to provide transparent and effective communication as we move forward together.

We would like to welcome Andrew Teno, a portfolio manager at Icahn Capital LP, to the Board and look forward to productive and collaborative engagement.

We also thank John Thompson for his years of service and contributions to Illumina as Chair of the Board. His deep executive experience and business knowledge were greatly valued during his tenure. John brought extensive technology
leadership, including as a CEO at Symantec and Virtual Instruments, and Chairman of the Board at Microsoft, to Illumina. His depth and breadth of knowledge in technology
and across a number of private and public sectors, as well as his financial
expertise, greatly contributed to the Board's strategic leadership of the company."

The company also noted that shareholders
approved the proposal to ratify auditors, one-year frequency on say-on-pay, and the stock incentive plan proposal; and shareholders
did not approve the company's say-on-pay proposal.

The results announced today are considered preliminary and are subject to certification by the independent Inspector of Elections. The final certified results are expected to be provided in a Current Report filed on Form 8-K with the U.S. Securities and Exchange Commission within the next four business days.

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding mandates, the future, business plans and other statements that are not historical in nature. These statements are made on the basis of Illumina's views and assumptions regarding future events and business performance and plans as of the time the statements are made. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms of similar meaning. Illumina does not undertake any obligation to update these statements unless required by applicable laws or regulations, and you should not place undue reliance on forward-looking statements. Specific factors are set forth in Illumina's Annual Report on Form 10-K for the year ended January 1, 2023 under the caption "Risk Factors", in information disclosed in public conference
calls, the date and time of which are released beforehand, and in filings with the Securities and Exchange Commission including, among others, quarterly reports on Form 10-Q.

Investors:
Salli Schwartz
858-291-6421
[email protected]

Media:
David McAlpine
347-327-1336
[email protected]

Steve Lipin
Gladstone Place Partners
212-230-5930

SOURCE Illumina, Inc.

MENAFN25052023003732001241ID1106316950


PR Newswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.